Company Background

Case overview: Takeda Pharmaceutical Company, Japan’s largest pharmaceutical firm with $45 billion market capitalization, faced a strategic crossroads when four of its top-selling China products were included in China’s Volume-Based Procurement (VBP, 带量采购, dàiliàng càigòu) program between 2019 and 2023. The company accepted price reductions of 65–85% on products representing 52% of its $2.1 billion China revenue — a decision that initially seemed financially devastating. Yet by 2024, Takeda had not only recovered but grown its China revenue to $2.4 billion, with innovative, VBP-exempt products rising from 38% to 61% of its portfolio. This case study dissects Takeda’s “China 4.0” strategy and offers a replicable playbook for foreign pharmaceutical companies confronting VBP.

Company Background

Founded in 1781 in Osaka as a traditional herbal medicine wholesaler, Takeda Pharmaceutical Company Limited (武田薬品工業, Takeda Yakuhin Kogyo) has evolved into a global top-10 pharmaceutical firm. The company’s transformation into a global powerhouse was catalyzed by its $62 billion acquisition of Shire plc in 2019, giving it deep portfolios in oncology, rare diseases, neuroscience, and gastroenterology. However, the Shire acquisition also left Takeda carrying approximately $31 billion in net debt, making China — the world’s second-largest pharmaceutical market — a critical source of revenue growth and cash flow.

Takeda established its first China operations in 1994, and by 2020 had built one of the largest China-based commercial organizations among foreign pharmaceutical companies. The company’s China portfolio spanned roughly 30 products across 10 therapeutic areas, including mature off-patent drugs like the hypertension medication Edarbi (azilsartan) and the diabetes drug Nesina (alogliptin), alongside innovative products like the oncology drug Ninlaro (ixazomib) and the gastroenterology treatment Entyvio (vedolizumab). Pre-VBP, Takeda’s China revenue stood at approximately ¥230 billion ($2.1 billion) in fiscal year 2019, representing roughly 12% of global revenue — making China Takeda’s third-largest individual market after the US and Japan.

The Challenge: VBP Impact on Core Portfolio

When China’s National Healthcare Security Administration (NHSA) launched the first VBP round in December 2018 with 25 drugs, Takeda initially assessed the risk as moderate. However, as VBP expanded across subsequent rounds, the threat became acute. Four of Takeda’s top-selling China products were directly impacted:

The aggregate impact was severe. By mid-2022, Takeda had lost roughly ¥68 billion ($620 million) in annualized China revenue from VBP-affected products — a decline of approximately 30% from its pre-VBP China baseline. However, Takeda’s China leadership recognized that VBP was not a temporary pricing shock but a permanent structural shift. The company responded with a comprehensive four-track strategy internally called “China 4.0.”

Strategic Response: The Four Tracks of China 4.0

Track 1: Aggressive VBP Participation with Cost Optimization

For off-patent products where Takeda had high market share and manufacturing scale, the company chose to bid aggressively rather than cede the market to domestic Chinese generics manufacturers. The most notable example was Edarbi (azilsartan). Despite taking a 78% price cut, Takeda secured VBP allocation in 27 of 31 provinces, resulting in a volume increase of over 300%. To maintain profitability, Takeda shifted production from its Tianjin plant to a lower-cost contract manufacturing organization (CMO) in Jiangsu province, reducing COGS by 40%. This “win the bid, then optimize the cost base” approach allowed Takeda to maintain brand presence and physician relationships even as pricing compressed.

Track 2: Accelerated Innovation Pipeline

Perhaps the most consequential strategic move was accelerating clinical development and regulatory approval of innovative drugs ineligible for VBP. Between 2020 and 2024, Takeda China obtained NMPA approval for seven new molecular entities (NMEs), including the rare disease drug Takhzyro (lanadelumab) for hereditary angioedema, the oncology drug Exkivity (mobocertinib) for EGFR exon20 insertion mutations, and Alunbrig (brigatinib) for ALK-positive non-small cell lung cancer. These launches leveraged China’s parallel review process, which allows drugs approved simultaneously in China, the US, and the EU to enter the Chinese market much faster than was historically possible.

Track 3: Strategic Partnerships with Chinese Biotech

Recognizing that organic innovation alone would not fill the VBP-created revenue gap quickly enough, Takeda aggressively pursued in-licensing and co-development deals with Chinese biotech firms. In 2021, Takeda entered a landmark $400 million partnership with Hangzhou-based Ascentage Pharma for the China rights to olverembatinib (a third-generation BCR-ABL inhibitor for CML), and a $320 million deal with Suzhou-based CNBX for a next-generation PARP inhibitor. By 2024, partnered products contributed roughly ¥45 billion in annual China revenue.

Track 4: Portfolio Triage and Divestment

Takeda made the difficult decision to divest or discontinue products caught in an unviable strategic position — too small to benefit from VBP volume guarantees but too large to ignore as cost centers. Between 2021 and 2023, Takeda China exited three therapeutic categories entirely, including its respiratory franchise (dominated by the inhaled corticosteroid Alvesco) and its vitamins and minerals supplement business. These divestments freed approximately ¥12 billion in annual SG&A spending, reallocated to innovative product launches and digital marketing capabilities.

Operational Structure and Key Changes

To execute its China 4.0 strategy, Takeda made significant operational changes:

• Local leadership empowerment: Takeda elevated its China president role to report directly to the global CEO’s office, shortening decision cycles from weeks to days. The China leadership team was granted authority to set local pricing, negotiate VBP bids up to ¥5 billion in annual revenue exposure, and approve local partnerships below $100 million without global board sign-off.
• Tianjin manufacturing upgrade: Takeda’s 60,000-square-meter Tianjin facility was retooled to manufacture both VBP-winning generics at low cost and specialized oncology injectables. The company invested ¥8 billion ($73 million) in a new aseptic processing line inaugurated in 2023.
• Digital-first commercial model: Takeda built a 200-person digital engagement team in Shanghai deploying AI-driven physician targeting, virtual MSL platforms, and a WeChat-based patient education ecosystem. By 2024, 45% of all physician interactions were conducted through digital channels, reducing field force costs by 30%.

Financial Impact and Results

By fiscal year 2024 (ending March 2025), Takeda’s China transformation showed measurable results:

Takeda’s 14% revenue increase from ¥230 billion to ¥262 billion over five years was far from the double-digit growth trajectories foreign pharma companies enjoyed in China before VBP. However, given the massive price deflation across the industry, Takeda significantly outperformed peers such as Pfizer (−8% China revenue) and Sanofi (−12%) over the same period. More importantly, the quality of Takeda’s China revenue improved dramatically — VBP-exposed revenue fell from 52% to 22%, meaning roughly ¥160 billion is now effectively insulated from further VBP price cuts.

Lessons for Foreign Pharma Companies

1. Accept VBP as permanent. Takeda’s early recognition that VBP was a structural shift enabled bold decisions (aggressive bidding, portfolio triage, manufacturing retooling) that reactive competitors delayed until too late. Foreign companies still maintaining premium pricing on mature products in 2025 face near-certain disruption in the next VBP round.
2. Distinguish VBP-win vs VBP-lose products. Not all products should be defended. Takeda’s disciplined triage assessed each product on manufacturing cost position, market share, brand equity, and substitutability. Products where scale was insufficient were exited.
3. Use VBP as an innovation catalyst. Takeda’s seven new NME approvals in four years — powered by China’s regulatory reforms and parallel review pathways — proved far more valuable than any price-defense strategy.
4. Build China-specific partnership capabilities. Takeda’s in-licensing engine, producing ¥45 billion from partnered products, relied on a 30-person Business Development team in Shanghai focused exclusively on China biotech deals.
5. Invest in digital commercial models. VBP’s arithmetic is simple: a 70% price cut needs 233% volume growth just to maintain revenue. Traditional face-to-face detailing cannot scale cost-effectively at those margins.

Looking Ahead

As of mid-2025, Takeda’s China 4.0 strategy continues to evolve. The company is investing heavily in a wholly owned R&D center in Shanghai’s Zhangjiang Hi-Tech Park, focused on China-priority indications such as hepatocellular carcinoma, nasopharyngeal carcinoma, and gastric cancer — cancers with significantly higher incidence in China than in Western markets. With innovative products now representing 61% of China revenue and a strong pipeline of 11 additional regulatory submissions planned through 2027, Takeda’s experience demonstrates that for foreign pharmaceutical companies willing to make hard strategic choices, China’s VBP era — while painful for legacy businesses — can be the foundation for a stronger, more innovative, and more resilient China franchise.